EVIDENCE SYNTHESIS FOR GLOBAL HEALTH: ANIMAL STUDIES UNDER THE LENS

Similar documents
Global progress in vaccine development

Vector control and policy: systematic reviews

Instrument for the assessment of systematic reviews and meta-analysis

Can we afford DAA for all???

Estimating TB burden. Philippe Glaziou World Health Organization Accra, Ghana

Update on TB Vaccines

UNICEF AND MALARIA MEDICINES. Supply Division October 2006

Alcohol interventions in secondary and further education

How to optimise immunisation: a live vaccine last policy. Frank Shann University of Melbourne

Analysis of the demand for a malaria vaccine: outcome of a consultative study in eight countries

RARE-Bestpractices Conference

Critical Thinking A tour through the science of neuroscience

Chemoprophylaxis and intermittent treatment for preventing malaria in children (Review)

The human immunodeficiency virus/acquired immune

GRADE tables to assist guideline development and recommendations. Plain Language Summary of Results

Copenhagen, Denmark, September August Malaria

Against intervention No recommendation Strong Conditional Conditional Strong. For intervention. High Moderate Low Very low

Why published medical research may not be good for your health

WG: Vaccinations and child survival Focus:

Antimicrobial resistance Fact sheet N 194 Updated April 2014

TB Vaccine Research and Development: Progress, Strategies and Controversies

Malaria. Edwin J. Asturias, MD

Behaviour Change: Supporting interventions for introduction of malaria RDTs in Cameroon & Nigeria

38 Current Concepts in

CEU screening programme: Overview of common errors & good practice in Cochrane intervention reviews

THE Price of a Pandemic 2017

School of Dentistry. What is a systematic review?

#4 (Tuberculosis OR TB OR Pulmonary Tuberculosis OR Multi-Drug Resistant Tuberculosis OR MDR OR Extremely-Drug Resistant Tuberculosis or XDR)

SPECIAL EVENT ON PHILANTHROPY AND THE GLOBAL PUBLIC HEALTH AGENDA. 23 February 2009, United Nations, New York Conference Room 2, 3:00 p.m. 6:00 p.m.

Gambling attitudes and misconceptions

Antimalarials in the WHO Essential Drugs List for Children Reviewer No.1

Improving Return on Public Health Investments in Disasters with Evidence Synthesis

Disclosure Information

Implementing the Abuja Declaration and Plan of Action: the journey so far

The potential public health impact of new TB vaccines

A New Class of Malaria Drugs: The Coartem Breakthrough from Novartis

HOW EFFECTIVE ARE ANTIVIRAL DRUGS AGAINST INFLUENZA? Dr Puja Myles

Factors affecting child development in developing countries

Accelerating progress towards the health-related Millennium Development Goals

The DIABETES CHALLENGE IN PAKISTAN FIFTH NATIONAL ACTION PLAN

Global health and vaccination: TB & beyond. Dr Mary Moran Executive Director

Novartis: tackling adherence. ESPACOMP, September, 2010

Crude health statistics

ART for prevention the task ahead

TB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director

Tanzania s Progress in Combating Malaria: Achievement and Challenges

Journal Assignment #2. Malaria Epidemics throughout the World

If I m interested, why is it a conflict? Ross McKinney, Jr, MD

Combination Anti-malarial Therapy and WHO Recommendations

Developing Logic Models

Monitoring tuberculosis progression using MRI and stereology

DEVELOPMENT. The European Union confronts HIV/AIDS, malaria and tuberculosis. A comprehensive strategy for the new millennium EUROPEAN COMMISSION

Suraj Madoori, Treatment Action Group, U.S. and Global Health Policy Director. On behalf of the Tuberculosis Roundtable

Monitoring of the achievement of the health-related Millennium Development Goals

Washington, DC, November 9, 2009 Institute of Medicine

RATING OF A RESEARCH PAPER. By: Neti Juniarti, S.Kp., M.Kes., MNurs

Funding Opportunities for Public Health Research

Copyright GRADE ING THE QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS NANCY SANTESSO, RD, PHD

What is new. Sandra Caldeira, Joint Research Centre

Ross Fund Summary January 2016

Understanding vaccine development

Update on TB Vaccines. Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town

EQUATOR Network: promises and results of reporting guidelines

Human Health Using nuclear techniques to improve health around the world

HIV-1 Vaccine Development Clinical Trials and Public Health Benefits Chaiyos Kunanusont HIV/AIDS Adviser United Nations Population Fund

The Johns Hopkins Vaccine Initiative Johns Hopkins Bloomberg School of Public Health

Cancer research investment should shift from late stage treatment to early stage detection No!

Ending Malaria in Nigeria: The WHO Agenda

The non-human primate model in TB vaccine development

Version for the Silent Procedure 29 April Agenda item January Hepatitis

USDA Nutrition Evidence Library: Systematic Review Methodology

The growing burden of noncommunicable diseases (NCDs)

Mathematical modelling to accelerate development of new tuberculosis vaccines

Overview of the Malaria Vaccine Implementation Programme (MVIP) Prof. Fred Were SAGE meeting 17 April, 2018

Determining the size of a vaccine trial

Avoiding common errors in research reporting:

Application of human epidemiological studies to pesticide risk assessment

Introduction to Experiments

ENDING AIDS, TB AND MALARIA AS EPIDEMICS

Issues in African Economic Development. Economics 172. University of California, Berkeley. Department of Economics. Professor Ted Miguel

MALARIA & POVERTY IN AFRICA

~Health and Development Initiative~

Malaria. Dr. Salim Abdulla, Director Ifakara Health Institute, Dar-es-salaam, Tanzania

Role of vaccination and the evaluation of LSD control programmes

Stakeholder preferred ways to reduce production diseases in broiler chickens and layer hens

BMGF MALARIA STRATEGY TO 2020

Investing for a Malaria-Free World

Catalytic Framework to End AIDS, TB and Eliminate Malaria in Africa by 2030

The Cochrane Collaboration s response to the aftermath of the tsunami

Data extraction. Specific interventions included in the review Dressings and topical agents in relation to wound healing.

Interpretation of the World Malaria Report Country Profile

Monitoring, Evaluation, Accountability, Learning (MEAL) Enabling Environment Finance for. Nutrition

Toyako Framework for Action on Global Health - Report of the G8 Health Experts Group -

Preparedness for candidate HCV vaccine trials in people who inject. C Vaccine Initiative*

UNIÃO AFRICANA ABUJA CALL FOR ACCELERATED ACTION TOWARDS UNIVERSAL ACCESS TO HIV AND AIDS, TUBERCULOSIS AND MALARIA SERVICES IN AFRICA

TB vaccine progress. Hassan Mahomed. Institute of Infectious Disease and Molecular Medicine, School of Child and Adolescent Health,

The WHO END-TB Strategy

Need for Chronic Viral Hepatitis Monitoring System

Special health needs of women and children

Government of Canada Federal AIDS Initiative Milestones

Transcription:

EVIDENCE SYNTHESIS FOR GLOBAL HEALTH: ANIMAL STUDIES UNDER THE LENS Paul Garner On behalf of the Cochrane infectious Diseases Group Editors And the Effective Health Care Research Programme Consortium

Competing interests Funded by the UK Aid Programme to increase the number of decisions based on reliable evidence in health for the poor in developing countries

previously UK Aid policies were well meaning, but based on expert opinion Example from the British Colonial Service for the Punjab

1993

Systematic reviews 1. Responses from our stakeholders over 20 yr. 2. Findings from a ASR of a new TB vaccine 3. Personal reflections on the agenda

Funders Synthesis Researchers Policy maker

Stakeholders Our funders

Research governance framework for health and social care (2001)

Global policy makers guidelines panels/advocates Category 1. Those that are happy

Amodiaquine (Lancet 1996) 50 studies Better than chloroquine WH O reintroduced in Africa 1998 Impregnated mosquito nets for malaria (Cochrane 1997) Low osmolarity ORS (BMJ/Cochrane 2001) 14 studies Reduced child mortality Helped underpin investment 1998-10 studies Better Changed formula 2003 Artemisinin combination Rx (Lancet 2004) 30 studies 70% increase in cure ACTs first line 2007 Artesunate severe malaria (Cochrane 2007) 8 studies 40% fewer deaths WHO rec 2008

Global policy makers guidelines panels/advocates Category 2. Those that are cross

Direct observation for TB (BMJ/Cochrane 1997) Deworming for schoolchildren (Cochrane 1996/2011) Primaquine single dose to block transmission (Cochrane 2012/4) 5 studies No difference Controversy Modified early 2000 50 studies Exaggerated claims Investment continued until recently 15 studies Inadequate data Policy remains; research continues

Belief disconfirmation bias Belief-confirming evidence: Belief-disconfirming evidence: taken at face value intense critical evaluation

Belief disconfirmation bias Standard responses: Original research methods is flawed Synthesis cannot be used here Data incomplete-studies missed You have applied the methods wrongly Synthesis authors are uninformed/ incompetent/trouble makers

Cochrane review Does routine deworming improve children s health, performance at school and contribute to economic development?

Deworming review: accountability in question One trial of 22,000 children in 60 clusters showed increased weight gain because it did not adjust for clustering A trial from Vietnam of over 300 children that looked at school performance has never been published One trial of 2 million children remained unpublished 6 years after recruitment ended Re-analysis of Miguel and Kremer study (Nov 2014) the claimed externality effects vanished & no effect on nutrition Plus one more

Increasingly Academic competing interests causes substantive biases and distortion Academic behaviour often challenges the principles of scientific integrity

Systematic review of prime boost TB vaccine Rufaro Kashangura, Emily S. Sena, Taryn Young, Paul Garner

Protocol driven study Comparison: vaccine + BCG vs. BCG Animals: any Design: TB challenge given Outcomes: Mortality/euthanasia, pathology in lungs, and bacterial loads in lung

Methods Comprehensive search Double application of inclusion criteria Study quality assessed Cumulative meta-analysis

quality

Criteria Were sample size and power calculations given? Was the number of animals clear? Was competing interest declared? Was there randomisation? Was there baseline comparability? Was the outcome assessor blind? Humane endpoint Pathology Bacteriol Williams Williams Goonetille Romano Tchilian Verrick Vorderme Sharpe 2005 (a) 2005 (b) ke 2003 2006 2008 2009 ier 2009 2010 No No No No No No No No Yes Yes No Yes No Yes Yes Yes No COI statement Not reported All 250-300g female pigs Not reported Not reported but objective Not reported No COI statement Not reported Same species pigs Not reported No COI statement Not reported All 8-10wk old female mice. Not reported No COI statement Not reported All 8-10 weeks old mice. Not reported No COI statement Not reported All 6-8wk old female mice. Not reported Contains COI with conflict Yes Same age weight, male macaques. Not reported Contains COI with conflict Not Reported All six month old cattle. No COI statemen t Not reported All 4 yr old macaque s. Not reported Yes Yes Only lesion volume blinded Not reported Not reported Not reported

Outcomes

Bacterial load

Pathology summary Authors conclusion Our interpretation William 2005 Guinea pigs Not able to discriminate No data provided (b) 14 William 2005 (b) 14 Guinea pigs Not significantly better than BCG No data provided Verrick 2009 c 18 Macaques BCG/MVA85A less severe disease and fewer lesions than BCG only Vordermeier 2009 1 Calves Sharpe 2010 12 Macaques significantly reduced after MVA85A vaccination compared to control f No statistical difference between MVA85A vaccinated and BCG vaccinated animals for lesions in lung, lung pathology and gross pathology scoring Scores in both BCG alone and MVA85A boost much lower than controls No direct statistical comparison between MVA85A and BCG. No statistical difference but more lesions in BCG and MVA85A groups. Other parameters show no trends

Mortality

Implications for strategy We as a group have a duty to develop the science and reviews in this area It has to be independent of the researchers The so called scientists will be sceptical (watch for belief disconfirmation bias ) We have to get FUNDERS and the PUBLIC onside